MARKET

AADI

AADI

Aadi Bioscience Inc
NASDAQ
1.780
-0.060
-3.26%
Closed 16:02 04/24 EDT
OPEN
1.850
PREV CLOSE
1.840
HIGH
1.850
LOW
1.760
VOLUME
110.34K
TURNOVER
0
52 WEEK HIGH
8.60
52 WEEK LOW
1.550
MARKET CAP
43.71M
P/E (TTM)
-0.7286
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AADI last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at AADI last week (0408-0412)?
Weekly Report · 04/15 09:59
Weekly Report: what happened at AADI last week (0401-0405)?
Weekly Report · 04/08 10:02
Weekly Report: what happened at AADI last week (0325-0329)?
Weekly Report · 04/01 10:01
Weekly Report: what happened at AADI last week (0318-0322)?
Weekly Report · 03/25 10:03
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
TipRanks · 03/18 10:15
Weekly Report: what happened at AADI last week (0311-0315)?
Weekly Report · 03/18 10:02
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With nab-Sirolimus At Society Of Gynecologic Oncology
Benzinga · 03/18 06:24
More
About AADI
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

Webull offers Aadi Bioscience Inc stock information, including NASDAQ: AADI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AADI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AADI stock methods without spending real money on the virtual paper trading platform.